Back to search results
NCT06561035

ACL-R Opioid Sparing Study

Enrolling by Invitation
PHASE3Ages 14–85InterventionalTreatment
Campbell Clinic
~56 participants
Updated 2024-08-19 on ClinicalTrials.gov
What's tested:Opiate SparingOpiate Based

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Visual Analog Scale
Measured over Once per day from postoperative day 1 to postoperative day 14; at two weeks follow up visit, 6 weeks follow up visit and 12 weeks follow up visit.
+1 more outcome measured

Conditions

Anterior Cruciate Ligament Injuries

Explore related trials

Injury of anterior cruciate ligament

Where it's being run

1 sites across 1 states
Tennessee1

Study leadership

  • Joseph Lamplot, MD · PRINCIPAL_INVESTIGATOR · Campbell Clinic

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

14-85 years of age.
Patients undergoing primary ACL-R with or without meniscus repair or meniscectomy, with or without chondroplasty.
Patients weigh at least 90lbs at time of enrollment.
Surgery scheduled at a Campbell Clinic Surgery Center (Midtown or Wolf River).
Willing and able to provide written informed consent.
Willing and able to cooperate with postoperative therapy.
Speak and read fluent English.

Exclusion

Multiligament knee reconstruction.
Pre-injury opioid consumption.
Substance abuse disorder (illicit drug abuse, alcoholism, etc).
Concomitant injuries or surgeries warranting pain medication (i.e. polytrauma patient).
Chronic pain syndrome.
Renal disease.
Currently taking selective serotonin reuptake inhibitors and/or serotonin and norepinephrine reuptake inhibitors.
Known sensitivity, allergy, or intolerance to medications within protocols.
History of diabetes.
Currently taking glucagon-like peptide 1 agonist.
Female patient who is pregnant on day of surgery or becomes pregnant during study period.

What this trial measures

  • Visual Analog ScaleOnce per day from postoperative day 1 to postoperative day 14; at two weeks follow up visit, 6 weeks follow up visit and 12 weeks follow up visit.

    Record pain score with 0 being no pain at all and 10 being worst pain possible.

  • Oral morphine equivalentdaily pill count from postoperative day 1 to postoperative day 14; at 2-week follow up visit, 6-week follow up visit and 12-week follow up visit.

    Opiate pill count